Aptalis Pharma

Aptalis Pharma develops and markets therapies for the treatment of gastrointestinal diseases and disorders.

Aptalis Pharma (known as Axcan Pharma until May 2011) is a privately-held, leading specialty pharmaceutical company that develops and markets a wide range of products to treat gastrointestinal diseases and disorders, such as inflammatory bowel disease, cholestatic liver diseases, irritable bowel syndrome, and complications related to pancreatic insufficiency. Aptalis hopes to improve the quality of care and health of patients suffering from gastrointestinal diseases and disorders by providing effective therapies for patients and their specialized caregivers. Aptalis was acquired by [TPG Capital](/organization/tpg-capital) in 2008, and it acquired [Eurand](/organization/eurand) in 2010. It [changed its name](http://www.thepressreleasewire.com/client/aptalispharma/release.jsp?actionFor=1437343&releaseSeq=0&year=2011) from Axcan Pharma to Aptalis in May 2011.